| 摘要 |
The method comprises regularly administering to a human or animal at least one precursor (I) which is converted in vivo to a mixt. (A) of eicosanoids. - Mixts. (A) comprise (1) PGE1, PGF1, TXA1, LTA3, LTC3 and LTD3 (derived from dihomo-gamma-linolenic acid, DGLA); (2) PGE2, PGF2, PGO2, prostacyclin, TXA2, LTA4, LTB4, LTC4, LTD4 and LTE4 (derived from arachidonic acid, AA), or (3) PGE3, PGF3, PGD3, delta-17-prostacyclin, TXA3, LTA5, LTB5 and LTC5 (derived from eicosapentaenoic acid, EPA). Specified (I) are gamma-linolenic acid (GLA), AA, EDA and their salts, derivs. and analogues. - (I) are administered at up to 100 mg per 100 hg of body wt. per day, esp. they are incorporated into foods or beverages. They have no adverse effects on normal cell growth. The method is useful for preventing cancer but not treatment of existing cancers. (0/5)
|
